

# SAFETY DATA SHEET



Revision date: 02-Apr-2014

Version: 2.0

Page 1 of 11

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

### Product Identifier

**Material Name:** EQUINE RHINOPNEUMONITIS VACCINE, KILLED VIRUS

**Trade Name:** Pneumabort K+1b  
**Compound Number:** 1525.21  
**Chemical Family:** Not determined

### Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

**Intended Use:** Veterinary Vaccine  
**Restrictions on Use:** Not for human use

### Details of the Supplier of the Safety Data Sheet

Zoetis Inc.  
100 Campus Drive, P.O. Box 651  
Florham Park, New Jersey 07932 (USA)  
Rocky Mountain Poison Control Center Phone: 1-866-531-8896  
Product Support/Technical Services Phone: 1-800-366-5288

Zoetis Belgium S.A.  
Mercuriusstraat 20  
1930 Zaventem  
Belgium

**Emergency telephone number:**  
**CHEMTREC (24 hours):** 1-800-424-9300  
**Contact E-Mail:** VMIPSrecords@zoetis.com

**Emergency telephone number:**  
**International CHEMTREC (24 hours):** +1-703-527-3887

## 2. HAZARDS IDENTIFICATION

**Appearance:** White to Pale Pink suspension

### Classification of the Substance or Mixture

**GHS - Classification** Not classified as hazardous

### EU Classification:

EU Indication of danger: Not classified

### Label Elements

**Signal Word:** Not Classified  
**Hazard Statements:** Non-hazardous in accordance with international standards for workplace safety.

### Other Hazards

**Short Term:** In the event of accidental injection, an allergic reaction may occur. If an allergic reaction occurs, the worker should be removed to the nearest emergency room and the appropriate therapy instituted. This product is an oil-adjuvanted suspension. Oil-adjuvant containing products may cause severe vasospasm following accidental injection.

### Australian Hazard Classification (NOHSC):

Non-Hazardous Substance. Non-Dangerous Goods.

## SAFETY DATA SHEET

Material Name: EQUINE RHINOPNEUMONITIS VACCINE,  
KILLED VIRUS  
Revision date: 02-Apr-2014

Page 2 of 11

Version: 2.0

**Note:** This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

**Hazardous**

| Ingredient         | CAS Number | EU EINECS/ELINCS List | EU Classification                                | GHS Classification                                                                                                                          | %    |
|--------------------|------------|-----------------------|--------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|------|
| Mineral oil, white | 8042-47-5  | 232-455-8             | Not Listed                                       | Not Listed                                                                                                                                  | 1    |
| Thimerosal         | 54-64-8    | 200-210-4             | T+; R26/27/28;<br>R33<br>N; R50/53               | Acute Tox. 2 (H300)<br>Acute Tox. 1 (H310)<br>STOT RE 2 (H373)<br>Acute Tox. 2 (H330)<br>Acute Aquatic 1 (H400)<br>Chronic Aquatic 1 (H410) | <0.1 |
| Polymyxin B        | 1404-26-8  | 215-768-4             | Xn;R22<br>Xn;R42/43                              | Acute Tox. 4 (H302)<br>Skin Sens. 1 (H317)<br>Resp Sens. 1 (H334)                                                                           | <0.1 |
| Formaldehyde       | 50-00-0    | 200-001-8             | T; R23/24/25<br>C; R34<br>Carc.Cat.3; R40<br>R43 | Acute Tox. 3 (H301)<br>Skin Corr. 1B (H314)<br>Skin Sens. 1 (H317)<br>Carc. 1A (H350)<br>Acute Tox. 3 (H331)                                | <0.1 |

| Ingredient                             | CAS Number   | EU EINECS/ELINCS List | EU Classification | GHS Classification | % |
|----------------------------------------|--------------|-----------------------|-------------------|--------------------|---|
| Amphotericin B                         | 1397-89-3    | 215-742-2             | Not Listed        | Not Listed         | * |
| Inactivated Equine Herpes virus type 1 | Not Assigned | Not Listed            | Not Listed        | Not Listed         | * |
| Polysorbate 60                         | 9005-67-8    | Not Listed            | Not Listed        | Not Listed         | * |
| Sorbitan monostearate                  | 1338-41-6    | 215-664-9             | Not Listed        | Not Listed         | * |
| Equine Herpesvirus type 1b             | Not Assigned | Not Listed            | Not Listed        | Not Listed         | * |
| Sodium Chloride Solution               | Not Assigned | Not Listed            | Not Listed        | Not Listed         | * |
| Neomycin Free Base                     | 1404-04-2    | 215-766-3             | Not Listed        | Not Listed         | * |

**Additional Information:** \* Proprietary  
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

## SAFETY DATA SHEET

Material Name: EQUINE RHINOPNEUMONITIS VACCINE,  
KILLED VIRUS  
Revision date: 02-Apr-2014

Page 3 of 11

Version: 2.0

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

#### Description of First Aid Measures

- Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
- Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
- Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
- Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

#### Most Important Symptoms and Effects, Both Acute and Delayed

- Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
- Medical Conditions Aggravated by Exposure:** None known

#### Indication of the Immediate Medical Attention and Special Treatment Needed

- Notes to Physician:** None

### 5. FIRE-FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO<sub>2</sub>, extinguishing powder, foam, or water.

#### Special Hazards Arising from the Substance or Mixture

- Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.
- Fire / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

#### Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

### 6. ACCIDENTAL RELEASE MEASURES

#### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

#### Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

#### Methods and Material for Containment and Cleaning Up

- Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
- Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

## SAFETY DATA SHEET

Material Name: EQUINE RHINOPNEUMONITIS VACCINE,  
KILLED VIRUS  
Revision date: 02-Apr-2014

Page 4 of 11

Version: 2.0

### 7. HANDLING AND STORAGE

#### Precautions for Safe Handling

Minimize generating airborne mists and vapors. Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

#### Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store as directed by product packaging.

**Incompatible Materials:** This material can be denatured or inactivated by a variety of organic solvents, salts or heavy metals.

**Specific end use(s):** No data available

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

#### Mineral oil, white

|                                    |                                 |
|------------------------------------|---------------------------------|
| ACGIH Threshold Limit Value (TWA)  | 5 mg/m <sup>3</sup>             |
| ACGIH Threshold Limit Value (STEL) | 10 mg/m <sup>3</sup> (oil mist) |

#### Sorbitan monostearate

|                                   |                      |
|-----------------------------------|----------------------|
| ACGIH Threshold Limit Value (TWA) | 10 mg/m <sup>3</sup> |
|-----------------------------------|----------------------|

#### Formaldehyde

|                                |                                                                         |
|--------------------------------|-------------------------------------------------------------------------|
| ACGIH Ceiling Threshold Limit: | 0.3 ppm                                                                 |
| ACGIH - Sensitizer Designation | Sensitizer                                                              |
| Australia STEL                 | 2 ppm                                                                   |
|                                | 2.5 mg/m <sup>3</sup>                                                   |
| Australia TWA                  | 1 ppm                                                                   |
|                                | 1.2 mg/m <sup>3</sup>                                                   |
| Austria OEL - MAKs             | 0.5 ppm                                                                 |
|                                | 0.6 mg/m <sup>3</sup>                                                   |
| Bulgaria OEL - TWA             | 1.0 mg/m <sup>3</sup>                                                   |
| Czech Republic OEL - TWA       | 0.5 mg/m <sup>3</sup>                                                   |
| Estonia OEL - TWA              | 0.5 ppm                                                                 |
|                                | 0.6 mg/m <sup>3</sup>                                                   |
| Finland OEL - TWA              | 0.3 ppm                                                                 |
|                                | 0.37 mg/m <sup>3</sup>                                                  |
| France OEL - TWA               | 0.5 ppm                                                                 |
| Germany (DFG) - MAK            | 0.3 ppm                                                                 |
|                                | 0.37 mg/m <sup>3</sup> no irritation should occur during mixed exposure |
| Greece OEL - TWA               | 2 ppm                                                                   |
|                                | 2.5 mg/m <sup>3</sup>                                                   |
| Hungary OEL - TWA              | 0.6 mg/m <sup>3</sup>                                                   |
| Ireland OEL - TWAs             | 2 ppm                                                                   |
|                                | 2.5 mg/m <sup>3</sup>                                                   |
| Japan - OELs - Ceilings        | 0.2 ppm                                                                 |
|                                | 0.24 mg/m <sup>3</sup>                                                  |
| Latvia OEL - TWA               | 0.5 mg/m <sup>3</sup>                                                   |

## SAFETY DATA SHEET

Material Name: EQUINE RHINOPNEUMONITIS VACCINE,  
KILLED VIRUS  
Revision date: 02-Apr-2014

Page 5 of 11

Version: 2.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

|                                         |                                   |
|-----------------------------------------|-----------------------------------|
| Lithuania OEL - TWA                     | 0.5 ppm<br>0.6 mg/m <sup>3</sup>  |
| Netherlands OEL - TWA                   | 0.15 mg/m <sup>3</sup>            |
| Vietnam OEL - TWAs                      | 0.5 mg/m <sup>3</sup>             |
| OSHA - Final PELs - TWAs:               | 0.75 ppm                          |
| OSHA - Specifically Regulated Chemicals | 2 ppm<br>0.5 ppm<br>0.75 ppm      |
| Poland OEL - TWA                        | 0.5 mg/m <sup>3</sup>             |
| Romania OEL - TWA                       | 1 ppm<br>1.20 mg/m <sup>3</sup>   |
| Slovakia OEL - TWA                      | 0.3 ppm<br>0.37 mg/m <sup>3</sup> |
| Slovenia OEL - TWA                      | 0.5 ppm<br>0.62 mg/m <sup>3</sup> |
| Sweden OEL - TWAs                       | 0.3 ppm<br>0.37 mg/m <sup>3</sup> |
| Switzerland OEL - TWAs                  | 0.3 ppm<br>0.37 mg/m <sup>3</sup> |

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

#### Polymyxin B

##### Zoetis OEB

OEB 2 - Sensitizer (control exposure to the range of 100ug/m<sup>3</sup> to < 1000ug/m<sup>3</sup>, provide additional precautions to protect from skin contact)

#### Exposure Controls

##### Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep air contamination levels below the exposure limits or within the OEB range listed above in this section.

##### Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

##### Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

##### Eyes:

Wear safety glasses or goggles if eye contact is possible.

##### Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

##### Respiratory protection:

Whenever excessive air contamination (dust, mist, vapor) is generated, respiratory protection, with appropriate protection factors, should be used to minimize exposure.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

#### Physical State:

Suspension

#### Color:

White to Pale pink

#### Odor:

No data available.

#### Odor Threshold:

No data available.

#### Molecular Formula:

Mixture

#### Molecular Weight:

Mixture

#### Solvent Solubility:

No data available

## SAFETY DATA SHEET

Material Name: EQUINE RHINOPNEUMONITIS VACCINE,  
KILLED VIRUS  
Revision date: 02-Apr-2014

Page 6 of 11

Version: 2.0

### 9. PHYSICAL AND CHEMICAL PROPERTIES

**Water Solubility:** No data available  
**pH:** No data available.  
**Melting/Freezing Point (°C):** No data available  
**Boiling Point (°C):** No data available.  
**Partition Coefficient: (Method, pH, Endpoint, Value)**  
No data available  
**Decomposition Temperature (°C):** No data available.

**Evaporation Rate (Gram/s):** No data available  
**Vapor Pressure (kPa):** No data available  
**Vapor Density (g/ml):** No data available  
**Relative Density:** No data available  
**Viscosity:** No data available

**Flammability:**

**Autoignition Temperature (Solid) (°C):** No data available  
**Flammability (Solids):** No data available  
**Flash Point (Liquid) (°C):** Non-flammable  
**Upper Explosive Limits (Liquid) (% by Vol.):** No data available  
**Lower Explosive Limits (Liquid) (% by Vol.):** No data available

**Polymerization:** Will not occur

### 10. STABILITY AND REACTIVITY

**Reactivity:** No data available  
**Chemical Stability:** Stable under normal conditions of use.  
**Possibility of Hazardous Reactions**  
**Oxidizing Properties:** None  
**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.  
**Incompatible Materials:** This material can be denatured or inactivated by a variety of organic solvents, salts or heavy metals.  
**Hazardous Decomposition Products:** No data available

### 11. TOXICOLOGICAL INFORMATION

**Information on Toxicological Effects**

**General Information:** The antigens included in this product are non-infectious. All have been prepared from killed or inactivated preparations of microorganisms. The information included in this section describes the potential hazards of the individual ingredients.

**Acute Toxicity: (Species, Route, End Point, Dose)**

**Thimerosal**

Rat Oral LD50 75 mg/kg  
Mouse Oral LD50 91 mg/kg  
Rat Subcutaneous LD50 98mg/kg

**Polymyxin B**

Mouse Oral LD50 790 mg/kg  
Mouse Para-periosteal LD50 3980ug/kg

## SAFETY DATA SHEET

Material Name: EQUINE RHINOPNEUMONITIS VACCINE,  
KILLED VIRUS  
Revision date: 02-Apr-2014

Page 7 of 11

Version: 2.0

### 11. TOXICOLOGICAL INFORMATION

Rat Subcutaneous LD50 50mg/kg

#### Polysorbate 60

Rat Oral LD50 64,000 mg/kg

#### Amphotericin B

Rat Oral LD50 > 5000 mg/kg  
Rat Para-periosteal LD50 1.6mg/kg  
Rat Intraperitoneal LD50 > 5000mg/kg  
Mouse Intravenous LD50 1.2mg/kg  
Mouse Intraperitoneal LD50 27.7mg/kg

#### Mineral oil, white

Rat Oral LD50 > 5000 mg/kg

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)

##### Thimerosal

Eye Irritation Rabbit Mild

##### Mineral oil, white

Skin Irritation Rabbit Slight  
Eye Irritation Rabbit Slight

##### Skin Irritation / Sensitization

This product contains formaldehyde and merthiolate which are considered to be skin sensitizers.

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

##### Amphotericin B

30 Day(s) Dog Intravenous 37 mg/kg/day LOAEL Kidney  
2 Month(s) Dog Intravenous 16.5 mg/kg/day LOAEL Kidney  
13 Week(s) Rat Oral 2 mg/kg/day NOAEL Male reproductive system, Female reproductive system  
13 Week(s) Dog Oral 1.6 mg/kg/day NOAEL Male reproductive system, Female reproductive system

#### Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

##### Amphotericin B

Embryo / Fetal Development Rat Oral 7.5 mg/kg/day NOAEL Not teratogenic, Fetotoxicity  
Embryo / Fetal Development Rabbit Oral 10 mg/kg/day NOAEL Not Teratogenic, Fetotoxicity

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

##### Polymyxin B

*In Vitro* Negative  
*In Vivo* Negative

##### Amphotericin B

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative  
*In Vivo* Micronucleus Mouse Negative  
*In Vitro* Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative

**SAFETY DATA SHEET**

Material Name: EQUINE RHINOPNEUMONITIS VACCINE,  
KILLED VIRUS  
Revision date: 02-Apr-2014

Page 8 of 11

Version: 2.0

**11. TOXICOLOGICAL INFORMATION**

**Carcinogen Status:** None of the components present in this material at concentrations equal to or greater than 0.1% are listed by IARC, NTP, OSHA, or ACGIH as a carcinogen.

**12. ECOLOGICAL INFORMATION**

**Environmental Overview:** The environmental characteristics of this material have not been fully evaluated. This product contains trace quantities of mercury, releases to the environment should be avoided.

**Toxicity:** No data available

**Persistence and Degradability:** No data available

**Bio-accumulative Potential:** No data available

**Mobility in Soil:** No data available

**13. DISPOSAL CONSIDERATIONS**

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater. This product contains trace quantities of mercury and may qualify as a RCRA Hazardous Waste. Status should be confirmed using the EPA Toxicity Characteristic Leaching Procedure (TCLP).

**Formaldehyde**  
RCRA - U Series Wastes  
Listed

**14. TRANSPORT INFORMATION**

The following refers to all modes of transportation unless specified below.  
Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

**15. REGULATORY INFORMATION**

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture



## SAFETY DATA SHEET

Material Name: EQUINE RHINOPNEUMONITIS VACCINE,  
KILLED VIRUS  
Revision date: 02-Apr-2014

Page 9 of 11

Version: 2.0

### 15. REGULATORY INFORMATION

#### Canada - WHMIS: Classifications

##### WHMIS hazard class:

Non-controlled

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

#### **Mineral oil, white**

|                                             |            |
|---------------------------------------------|------------|
| CERCLA/SARA 313 Emission reporting          | Not Listed |
| California Proposition 65                   | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present    |
| Australia (AICS):                           | Present    |
| EU EINECS/ELINCS List                       | 232-455-8  |

#### **Amphotericin B**

|                                                               |            |
|---------------------------------------------------------------|------------|
| CERCLA/SARA 313 Emission reporting                            | Not Listed |
| California Proposition 65                                     | Not Listed |
| Australia (AICS):                                             | Present    |
| Standard for the Uniform Scheduling<br>for Drugs and Poisons: | Schedule 4 |
| EU EINECS/ELINCS List                                         | 215-742-2  |

#### **Inactivated Equine Herpes virus type 1**

|                                    |            |
|------------------------------------|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65          | Not Listed |
| EU EINECS/ELINCS List              | Not Listed |

#### **Polysorbate 60**

|                                             |            |
|---------------------------------------------|------------|
| CERCLA/SARA 313 Emission reporting          | Not Listed |
| California Proposition 65                   | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present    |
| Australia (AICS):                           | Present    |
| EU EINECS/ELINCS List                       | Not Listed |

#### **Sorbitan monostearate**

|                                             |            |
|---------------------------------------------|------------|
| CERCLA/SARA 313 Emission reporting          | Not Listed |
| California Proposition 65                   | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present    |
| Australia (AICS):                           | Present    |
| EU EINECS/ELINCS List                       | 215-664-9  |

#### **Equine Herpesvirus type 1b**

|                                    |            |
|------------------------------------|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
|------------------------------------|------------|

## SAFETY DATA SHEET

Material Name: EQUINE RHINOPNEUMONITIS VACCINE,  
KILLED VIRUS  
Revision date: 02-Apr-2014

Page 10 of 11

Version: 2.0

### 15. REGULATORY INFORMATION

|                                                                       |                                    |
|-----------------------------------------------------------------------|------------------------------------|
| California Proposition 65                                             | Not Listed                         |
| EU EINECS/ELINCS List                                                 | Not Listed                         |
| <b>Sodium Chloride Solution</b>                                       |                                    |
| CERCLA/SARA 313 Emission reporting                                    | Not Listed                         |
| California Proposition 65                                             | Not Listed                         |
| EU EINECS/ELINCS List                                                 | Not Listed                         |
| <b>Thimerosal</b>                                                     |                                    |
| CERCLA/SARA 313 Emission reporting                                    | Not Listed                         |
| California Proposition 65                                             | Not Listed                         |
| Inventory - United States TSCA - Sect. 8(b)                           | Present                            |
| Australia (AICS):                                                     | Present                            |
| EU EINECS/ELINCS List                                                 | 200-210-4                          |
| <b>Polymyxin B</b>                                                    |                                    |
| CERCLA/SARA 313 Emission reporting                                    | Not Listed                         |
| California Proposition 65                                             | Not Listed                         |
| EU EINECS/ELINCS List                                                 | 215-768-4                          |
| <b>Neomycin Free Base</b>                                             |                                    |
| CERCLA/SARA 313 Emission reporting                                    | Not Listed                         |
| California Proposition 65                                             | Not Listed                         |
| Standard for the Uniform Scheduling<br>for Drugs and Poisons:         | Schedule 4                         |
| EU EINECS/ELINCS List                                                 | 215-766-3                          |
| <b>Formaldehyde</b>                                                   |                                    |
| CERCLA/SARA 313 Emission reporting                                    | 0.1 %                              |
| CERCLA/SARA Hazardous Substances<br>and their Reportable Quantities:  | 100 lb                             |
|                                                                       | 45.4 kg                            |
| CERCLA/SARA - Section 302 Extremely Hazardous<br>TPQs                 | 500 lb                             |
| CERCLA/SARA - Section 302 Extremely Hazardous<br>Substances EPCRA RQs | 100 lb                             |
| California Proposition 65                                             | carcinogen initial date 1/1/88 gas |
| OSHA - Specifically Regulated Chemicals                               | 2 ppm                              |
|                                                                       | 0.5 ppm                            |
|                                                                       | 0.75 ppm                           |
| Inventory - United States TSCA - Sect. 8(b)                           | Present                            |
| Australia (AICS):                                                     | Present                            |
| Standard for the Uniform Scheduling<br>for Drugs and Poisons:         | Schedule 2                         |
|                                                                       | Schedule 6                         |
| EU EINECS/ELINCS List                                                 | 200-001-8                          |

### 16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

## SAFETY DATA SHEET

**Material Name:** EQUINE RHINOPNEUMONITIS VACCINE,  
KILLED VIRUS  
**Revision date:** 02-Apr-2014

Page 11 of 11

Version: 2.0

---

Acute toxicity, oral-Cat.2; H300 - Fatal if swallowed  
Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed  
Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed  
Acute toxicity, dermal-Cat.1; H310 - Fatal in contact with skin  
Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage  
Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction  
Acute toxicity, inhalation-Cat.2; H330 - Fatal if inhaled  
Acute toxicity, inhalation-Cat.3; H331 - Toxic if inhaled  
Sensitization, respiratory-Cat.1; H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled  
Carcinogenicity-Cat.1A; H350 - May cause cancer  
Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure  
Hazardous to the aquatic environment, acute toxicity-Cat.1; H400 - Very toxic to aquatic life  
Hazardous to the aquatic environment, chronic toxicity-Cat.1; H410 - Very toxic to aquatic life with long lasting effects

Carcinogenic: Category 3

C - Corrosive

T+ - Very toxic

T - Toxic

N - Dangerous for the environment

Xn - Harmful

R22 - Harmful if swallowed.

R33 - Danger of cumulative effects.

R34 - Causes burns.

R40 - Limited evidence of a carcinogenic effect

R43 - May cause sensitization by skin contact.

R23/24/25 - Toxic by inhalation, in contact with skin and if swallowed.

R26/27/28 - Very toxic by inhalation, in contact with skin and if swallowed.

R42/43 - May cause sensitization by inhalation and skin contact.

R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

**Data Sources:** The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

**Reasons for Revision:** Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection.

**Prepared by:** Toxicology and Hazard Communication  
Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**